source
- AstraZeneca’s heart drug Wainua fails late-stage trial, raising 2027 outlook concernsAstraZeneca announced that its experimental heart disease therapy, Wainua, did not meet primary endpoints in a Phase III trial conducted in July. The failure is a setback for the company, whose pi…
- Biogen sees continued revenue growth and pipeline readouts, M&A not essential, CEO saysBiogen reported third‑quarter earnings, marking a third straight quarter of revenue growth driven by its marketed products. The increase stemmed from higher sales of the Alzheimer’s therapy Leqemb…